News and Press Releases
Verdemed is proud to sponsor The Latin America Regional Cannabis Report: 2019 Industry Outlook (New Frontier Data).
“The purpose of the report is to provide an overview of cannabis legalization and regulation trends and issues in key Latin American markets in order to support operators and investors in guiding business strategy for emerging sectors.”.
Download PDF (Executive Summary)
Cannabis: Wayland Group reaches out to Verdemed
January 11, 2019, São Paulo - O Globo, online.
Two executives from Wayland Group, a Canadian company that sells cannabis-based products, are in Brazil to make a proposal to Verdemed, a start-up that includes Brazilians among its founders.
Wayland wants to buy 10% of Verdemed for US$6 million. Focused on cannabis-based products, the company is valued at US$54 million.
For Wayland, which has operations all over the world, the main appeal of Verdemed is its operations in Latin America, especially in Brazil and Chile.
The plan, which is still at an early stage, is to fold it into a new company of global scale, to be created by Wayland.
The discussions are serious and, if it succeeds, the deal should close before Carnival, which this year takes place in March.
Link in Portuguese only:
Brazilians change life and country to invest in legalized cannabis
Initiatives range from websites to courses and medicines
December 02, 2018, São Paulo - O Globo, online.
[…] Executive José Bacellar, who has lived in Canada for ten years, noticed the move in the market last year and decided to change the scenery…
[…] Bacellar met with other Brazilian executives and doctors to set up Verdemed, a medical cannabis company. Since then, he says, he spends half the time in the air: between Chile, Colombia, Uruguay, Mexico, Brazil and the United States. Before opening the business, he still spent three months in London at an internship following biotechnology laboratories applied to medical cannabis. Your company takes care of everything from planting to delivering medicines to patients.….
Continue reading here:
Verdemed invests in cannabis-based medications.
November 12, 2018, São Paulo - Valor Econômico, in print and online.
VerdeMed, among whose founders are executives and doctors from Brazil and Colombia, plans to raise about US$20 million over the next two years to invest in the development of cannabis-based medications. The first funding round, with a goal of raising US$6 million, attracted the interest of Brazilian investors and may be concluded in 2018. Another two rounds are planned for 2019 and 2020 and, if progress is as scheduled, the goal is for an initial public offering in 2021 in Canada, where the company’s headquarters are located.….
In Brazil, marijuana startups wait for change in legislation to act.
October 14, 2018, São Paulo - O Estado de São Paulo, in print and online.
Despite drug commerce being illegal in the Country, companies created to explore the medicinal use of the substance attract investors.
The market of marijuana has always been lucrative - but illegal. On the american continent, one of the first countries to change its rules was Uruguay, who regulated the production and commercialization of cannabis in 2013. Canada, Colombia, Peru, Mexico and over 20 USA states have also altered their legislation, each with their own particularities, in favor of the legal commerce of the drug. The result was the birth of promising new businesses…
Verdemed Looks to Raise $5M to Acquire Colombian Licensed Producer & Brazilian Lab
October 2, 2018, Toronto - CISION, online.
VERDEMED HOLDINGS INC. (“VerdeMed” or the “Company”) is pleased to announce that it is undertaking an equity offering for gross proceeds up to US$5 million and, to date, has received US$600,000 in funding commitments from Brazilian and Colombian qualified investors. The Company plans to use the proceeds of the offering to complete strategic asset acquisitions in Colombia and Brazil and to further its business plans.
VerdeMed holds rights to acquire a significant stake in a Colombian Licenced Producer -LP, which currently has a 3,000 sq ft indoor growing and industrial extraction facility, together with an option to buy the remaining interest in the LP. The LP is operational and fully licensed to plant, grow, extract, formulate and sell medicinal cannabis products. The LP plans to harvest its first crop and complete its initial medicinal cannabis oil sales by the end of this year…
Download pdf or read online below: